Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management
Journal article
Gao N. et al, (2024), PharmacoEconomics
Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults.
Journal article
Koychev I. et al, (2024), BMJ Open, 14
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
Journal article
Adler AI. et al, (2024), Lancet
Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? insights from post-hoc analysis of EXSCEL.
Journal article
Gooding KM. et al, (2024), Diabetes Res Clin Pract
Regional variation in cause of death in patients with type 2 diabetes: Insights from EXSCEL.
Journal article
Rao VN. et al, (2024), Am Heart J, 271, 123 - 135
Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.
Journal article
Morrow LM. et al, (2024), J Diabetes, 16
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Journal article
Cardoso P. et al, (2024), Diabetologia
Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.
Journal article
Juraschek SP. et al, (2023), JAMA, 330, 1459 - 1471
Timing of SGLT2i initiation after acute myocardial infarction.
Journal article
von Lewinski D. et al, (2023), Cardiovasc Diabetol, 22
Aetiology of Type 2 diabetes in people with a 'normal' body mass index: Testing the Personal Fat Threshold Hypothesis.
Journal article
Taylor R. et al, (2023), Clin Sci (Lond)
Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes.
Journal article
Regan JA. et al, (2023), JCI Insight
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Journal article
Hundertmark MJ. et al, (2023), Circulation, 147, 1654 - 1669
Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Journal article
Bethel MA. et al, (2023), Cardiovasc Diabetol, 22
Association of osteocalcin, osteoprotegerin and osteopontin with cardiovascular disease and retinopathy in type 2 diabetes.
Journal article
Maddaloni E. et al, (2023), Diabetes Metab Res Rev
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.
Journal article
Othonos N. et al, (2023), Nat Commun, 14
Joint longitudinal and time-to-event modeling compared with standard Cox modeling in patients with type 2 diabetes with and without established cardiovascular disease: an analysis of the EXSCEL trial.
Journal article
Oulhaj A. et al, (2023), Diabetes Obes Metab
Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials
Journal article
Maddaloni E. et al, (2023), Diabetes, Obesity and Metabolism
Precision medicine in type 2 diabetes: development and validation of a treatment selection algorithm for SGLT2-inhibitors and GLP1-receptor agonist therapies
Conference paper
Cardoso P. et al, (2023), DIABETOLOGIA, 66, S30 - S30
Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
Journal article
Green JB. et al, (2023), Diabetes, Obesity and Metabolism
UKPDS blood pressure study 34 year follow-up
Conference paper
Coleman RL. et al, (2023), DIABETOLOGIA, 66, S96 - S96